01:15am Monday 13 July 2020

VTT's hyperspectral camera shows promising results in detection of skin field cancerization

The hand-held, mobile hyperspectral camera images the skin region in two seconds. The large field of view (12 cm2) enables the detection of large skin areas at once.

In the pilot study, the camera has been used to detect the skin areas with field cancerization i.e. areas of multiple skin cancer precursors, actinic keratoses, for early treatment of the affected areas. The hyperspectral camera has also been used to detect the borders of poorly delineated skin tumours, such as lentigo malignas, which are difficult to detect by the naked eye, in order to avoid the need for re-excisions. The preliminary results are promising.

Developed by VTT on the basis of the Fabry-Perot interferometer, the hyperspectral camera captures images in up to 70 narrow wavelengths, whereas a regular camera uses only three. The spectral image generated is a three-dimensional cube built of numerous layers of greyscale images, each of which has been taken within a limited wavelength range. A spectrum for each pixel of the spectral image is formed by the images within the cube. Different biological tissues can be identified by their reflected spectra in hyperspectral images. Computational methods are used to interpret these images, in order to determine the position and size of the tumour to be treated. In the ongoing pilot study, all results are being verified by histopathological sampling.

Patents have been granted for the hyper-spectral camera in the USA and in Finland. Heikki Saari, Principal Scientist at VTT, is the inventor of this patented device.

Skin cancer rates have been growing exponentially, due to population ageing and UV damage caused by excessive exposure to sunlight.

The camera is owned by the University of Jyväskylä. It can also be used for various applications of a more general nature.

Photo: Weighing just over 1 kg, the hyper-spectral camera detects skin cancer in real time. (Photo: Ilkka Pölönen)

Additional information

Heikki Saari
Principal Scientist
+358 40 589 1254

Noora Neittaanmäki-Perttu
LL, Resident in Dermatology, Skin and Allergy Hospital, Helsinki University Central Hospital
[email protected]

Ilkka Pölönen
Project Researcher, University of Jyväskylä
+358 400 248 140, [email protected]


Share on:
or:

Health news